» Articles » PMID: 20078677

Psychopathology in Methamphetamine-dependent Adults 3 Years After Treatment

Overview
Specialty Psychiatry
Date 2010 Jan 19
PMID 20078677
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction And Aims: Although psychiatric symptoms are frequently observed in methamphetamine (MA) users, little is known about the prevalence of psychiatric disorders in MA-dependent individuals. This is the first study to examine the association of psychiatric disorders with substance use and psychosocial functioning in a large sample of MA users 3 years after treatment. We predicted that psychiatric diagnoses and severity would be associated with substance use and poorer overall functioning over the 3 year post-treatment course.

Design And Methods: Participants (N = 526) received psychosocial treatment for MA dependence as part of the Methamphetamine Treatment Project and were reassessed for psychosocial functioning and substance use at a mean of 3 years after treatment initiation. DSM-IV psychiatric diagnoses were assessed at follow-up using the Mini-International Neuropsychiatric Interview. Psychosocial functioning was assessed using the Addiction Severity Index.

Results: Overall, 48.1% of the sample met criteria for a current or past psychiatric disorder other than a substance use disorder. Consistent with prior reports from clinical samples of cocaine users, this rate was largely accounted for by mood disorders, anxiety disorders and antisocial personality. Those with an Axis I psychiatric disorder evidenced increased MA use and greater functional impairment over time relative to those without a psychiatric disorder.

Discussion And Conclusions: This initial investigation of psychiatric diagnoses in MA users after treatment indicates elevated rates of Axis I and II disorders in this population and underscores the need for integrated psychiatric assessment and intervention in drug abuse treatment settings.

Citing Articles

Major Depression in Comorbidity with Substance use Disorders: Patients' Features and Clinical-Neurobiological Rationale of Antidepressant Treatments.

De Filippis S, Martinotti G, Nicoletti F, Mastrostefano A, Trovini G, Pugliese A Curr Neuropharmacol. 2024; 23(3):256-275.

PMID: 39219428 PMC: 11808588. DOI: 10.2174/1570159X22666240827165327.


Active learning impairments in substance use disorders when resolving the explore-exploit dilemma: A replication and extension of previous computational modeling results.

Taylor S, Lavalley C, Hakimi N, Stewart J, Ironside M, Zheng H Drug Alcohol Depend. 2023; 252:110945.

PMID: 37717307 PMC: 10635739. DOI: 10.1016/j.drugalcdep.2023.110945.


Active learning impairments in substance use disorders when resolving the explore-exploit dilemma: A replication and extension of previous computational modeling results.

Taylor S, Lavalley C, Hakimi N, Stewart J, Ironside M, Zheng H medRxiv. 2023; .

PMID: 37066197 PMC: 10104213. DOI: 10.1101/2023.04.03.23288037.


Increased Lipid Peroxidation and Lowered Antioxidant Defenses Predict Methamphetamine Induced Psychosis.

Al-Hakeim H, Altufaili M, Almulla A, Moustafa S, Maes M Cells. 2022; 11(22).

PMID: 36429122 PMC: 9688750. DOI: 10.3390/cells11223694.


The Association of High-Frequency Nut Intake With a Low Risk of Psychological Problems in Female Methamphetamine Users.

Song Z, Dong F, Liu Y, Liu G, Li B, Pang X Front Psychiatry. 2022; 13:878859.

PMID: 36046161 PMC: 9421136. DOI: 10.3389/fpsyt.2022.878859.


References
1.
Zweben J, Cohen J, Christian D, Galloway G, Salinardi M, Parent D . Psychiatric symptoms in methamphetamine users. Am J Addict. 2004; 13(2):181-90. DOI: 10.1080/10550490490436055. View

2.
Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

3.
Grant B, Stinson F, Dawson D, Chou S, Dufour M, Compton W . Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004; 61(8):807-16. DOI: 10.1001/archpsyc.61.8.807. View

4.
McLellan A, Luborsky L, Woody G, OBrien C . An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980; 168(1):26-33. DOI: 10.1097/00005053-198001000-00006. View

5.
Ritsher J, McKellar J, Finney J, Otilingam P, Moos R . Psychiatric comorbidity, continuing care and mutual help as predictors of five-year remission from substance use disorders. J Stud Alcohol. 2003; 63(6):709-15. DOI: 10.15288/jsa.2002.63.709. View